Select Initial Public Offering Representations

• Viela Bio, Inc. in its $150 million initial public offering.
• NuCana plc. in its $114 million initial public offering. 
• Quanterix Corporation in its $73.7 million initial public offering.

Select Follow-on Offering and Alternate Transaction Representations

• Intra-Cellular Therapies, Inc. in multiple offerings, including its $350 million follow-on offering, its $295 million follow-on offering, and its $150 million follow-on offering. 
• Albireo Pharma, Inc. in multiple offerings, including its $160 million follow-on offering and its $65 million follow-on offering. 
• Viela Bio, Inc. in multiple offerings, including its $170 million follow-on offering. 
• Nucana plc. in multiple offerings, including its $70 million follow-on offering.
• J.P. Morgan, SVB Leerink, and Cowen in Acceleron Pharma Inc.’s $493 million follow-on offering.
• Goldman Sachs, Morgan Stanley, J.P. Morgan, and Cowen in GW Pharmaceuticals plc.’s $345 million follow-on offering.
• Goldman Sachs and Leerink Partners in a $50.5 million secondary offering of Achillion Pharmaceuticals, Inc.’s common stock by selling stockholder Johnson & Johnson Innovation-JJDC, Inc.
• Leerink Partners in ArQule, Inc.’s $65 million follow-on offering.

Select Mergers and Acquisitions Representations

• Albireo Pharma, Inc. in its reverse merger with Biodel Inc.
• F-star Therapeutics, Inc. in its reverse merger with Spring Bank Pharmaceuticals.